Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published August 28, 2012 | Supplemental Material + Published
Journal Article Open

High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45

Abstract

Many cellular signaling events are regulated by tyrosine phosphorylation and mediated by the opposing actions of protein tyrosine kinases and phosphatases. Protein tyrosine phosphatases are emerging as drug targets, but poor cell permeability of inhibitors has limited the development of drugs targeting these enzymes [Tautz L, et al. (2006) Expert Opin Ther Targets 10:157–177]. Here we developed a method to monitor tyrosine phosphatase activity at the single-cell level and applied it to the identification of cell-permeable inhibitors. The method takes advantage of the fluorogenic properties of phosphorylated coumaryl amino propionic acid (pCAP), an analog of phosphotyrosine, which can be incorporated into peptides. Once delivered into cells, pCAP peptides were dephosphorylated by protein tyrosine phosphatases, and the resulting cell fluorescence could be monitored by flow cytometry and high-content imaging. The robustness and sensitivity of the assay was validated using peptides preferentially dephosphorylated by CD45 and T-cell tyrosine phosphatase and available inhibitors of these two enzymes. The assay was applied to high-throughput screening for inhibitors of CD45, an important target for autoimmunity and infectious diseases [Hermiston ML, et al. (2003) Annu Rev Immunol 21:107–137]. We identified four CD45 inhibitors that showed activity in T cells and macrophages. These results indicate that our assay can be applied to primary screening for inhibitors of CD45 and of other protein tyrosine phosphatases to increase the yield of biologically active inhibitors.

Additional Information

© 2012 National Academy of Sciences. Edited by Arthur Weiss, University of California, San Francisco, CA, and approved July 16, 2012 (received for review March 27, 2012). Published online before print August 13, 2012. We thank Krishna Kota and Robert C. Boltz for their help with high-content image analysis and Klaus Ley for critically reading the manuscript. This work was supported by an Inter-Disciplinary Zumberge grant at the University of Southern California (USC) (to N.B. and A.M.B.), by National Institutes of Health (NIH) Grants DK080165 (to N.B. and A.M.B.); GM079386 (to A.M.B.); CA126937, CA152194, and CA079954 (to Z.Y.Z.); and by the Department of Defense Chemical Biological Defense Program through the Defense Threat Reduction Agency Transformational Medical Technologies Program TMTI.DRUG.02.10.RD.001 (to R.G.P.) and TMTI0048_09_RD_T (to S.B.). S.M.S. was supported by the NIH Training Grant in Cellular, Biochemical, and Molecular Biology at USC. Author contributions: S.M.S., R.G.P., Z.-Y.Z., S.B., A.M.B., and N.B. designed research; S.M.S., R.G.P., L.M.W., D.J.W., M.D.F., S.M., S.S.D., D.R., T.K., and S.Z. performed research; S.M.S., R.G.P., Z.-Y.Z., A.M.B., and N.B. analyzed data; and S.M.S., A.M.B., and N.B. wrote the paper. The authors declare no conflict of interest.

Attached Files

Published - PNAS-2012-Stanford-13972-7.pdf

Supplemental Material - pnas.201205028SI.pdf

Files

pnas.201205028SI.pdf
Files (2.3 MB)
Name Size Download all
md5:8e8c7054d9fe978b36637967bff697ed
1.5 MB Preview Download
md5:3850185aac9b05d3a30576249ea987b9
777.4 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 19, 2023